AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The group wants to improve on its own Welireg in a new phase 3 trial.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
